{"entity":{"id":"nct07169851","kind":"trial","name":"A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer","aka":[],"tldr":"A phase 2 trial of LY3537021 in advanced solid tumours, run by Eli Lilly and Company, now recruiting.","summary":"A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer is a phase 2 interventional study registered as NCT07169851 by Eli Lilly and Company, with 204 participants planned, started 2025-11-28 and due to reach its primary completion in 2026-12. Interventions recorded: LY3537021, Placebo, Standard of Care Antiemetic Therapies and Background Chemotherapy.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07169851","url":"https://clinicaltrials.gov/study/NCT07169851"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["eli-lilly"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07169851","phase":"2","setting":"A Phase 2, Double-blind, Placebo-Controlled Study to Evaluate LY3537021 for the Treatment of Chemotherapy-Induced Nausea and Vomiting in Adult Participants With Malignant Disease","sponsor":"Eli Lilly and Company","enrolled":204,"outcomes":[]},"route":"/trials/nct07169851/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"eli-lilly","kind":"company","name":"Eli Lilly (incl. Loxo)","route":"/companies/eli-lilly/"}]}}